The pharmaceutical industry is currently witnessing a historic gold rush surrounding obesity treatments. While industry titans like Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) dominate the headlines and the pharmacy shelves, the market remains hungry for a third player to disrupt the status quo. Supply shortages and high prices have created a massive opening for agile competitors, and Viking Therapeutics (NASDAQ: VKTX) has emerged as the most advanced, clinical-stage challenger in the field.
Trading around $34 as of late February, Viking represents a distinct alternative for investors. It is not a stable, dividend-paying giant—it is a high-beta growth play. This means the stock offers significantly higher volatility than the broader sector, but also higher potential upside. Viking stands at a crossroads, balancing the potential of a massive buyout premium against the operational risks of challenging the world’s largest drugmakers on their own turf.
